Abbott Laboratories (0Q15)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 103.31 |
|---|---|
| 52-week range | 42.26 – 136.17 |
| Return, 1 month / 3 months | +2.9% / −1.4% |
| Return, 1 year / 3 years | −17.0% / +18.5% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 53 |
| Volatility (1 year) | 27.3% |
| Worst drawdown (1 year) | -36.5% |
| Average daily value traded | 0.94M USD |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Abbott Laboratories is a healthcare company that develops and makes medical devices, diagnostic tests, nutritional products and branded generic medicines. Its customers include hospitals, clinics, laboratories and consumers, and its nutrition range covers infant formula and adult nutritional drinks. The company is based in Abbott Park, Illinois, in the United States, and it operates across many countries, serving patients and healthcare professionals with products for heart care, diabetes management and general health.
The shares are listed on the London Stock Exchange in UK under the code 0Q15, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Abbott Laboratories (0Q15) trades on the London Stock Exchange in UK. It last closed at USD 103.31 on 27 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 2,009 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 17.0% and over the last three months it fell 1.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 54 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.8% | ||
| From 52-week high | -21.3% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -1.4% | ||
| 6-month return | 13.1% | ||
| 12-month return, skipping the last month | -19.3% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.5% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.94M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.5% |
|---|---|
| 1 month | +2.9% |
| 3 months | −1.4% |
| 6 months | +13.1% |
| 1 year | −17.0% |
| 3 years | +18.5% |
| 5 years | −10.8% |
Signals
| 50-day / 200-day average | 104.42 / 100.48 |
|---|---|
| Golden / death cross (60 days) | Golden, 35 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.48 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | USD 0.6300 |
| 15 Jul 2026 | USD 0.6300 |
| 15 Apr 2026 | USD 0.6300 |
| 15 Jan 2026 | USD 0.6300 |
| 15 Oct 2025 | USD 0.5900 |
| 15 Jul 2025 | USD 0.5900 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.